Related Experiment Video
Updated: Nov 16, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Diazoxide-associated pulmonary hypertension in a patient with noncompaction cardiomyopathy
Rachel T Sullivan1, Kathryn A Tillman1, Steven J Kindel1
1Medical College of Wisconsin, Children's Hospital of Wisconsin, Milwaukee, WI, USA.
Abstract:
Development of pulmonary hypertension after initiation of diazoxide for the treatment of neonatal hyperinsulinemic hypoglycemia is a rare, but previously described association. Risk factors for development of diazoxide-associated pulmonary hypertension include lower gestational age and congenital heart disease. This novel case report describes an infant with noncompaction cardiomyopathy who developed pulmonary hypertension shortly after initiation of diazoxide for hyperinsulinemic hypoglycemia which resolved upon cessation of the drug. This case highlights the benefit of having pre-treatment knowledge of underlying cardiac anatomy and makes a case for routine echocardiographic screening for neonates initiating diazoxide treatment.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy VI: Nursing Management
Cardiomyopathy I: Introduction and Classification
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...

